openPR Logo
Press release

Tumor Necrosis Factor Inhibitors Market and Clinical Pipeline Outlook 2022 Report

05-07-2018 06:39 AM CET | Health & Medicine

Press release from: Kuick Resarch

Tumor Necrosis Factor Inhibitors Market and Clinical Pipeline

“Tumor Necrosis Factor Inhibitors Market and Clinical Pipeline Outlook 2022” Report Highlight:


* Overview of Tumor Necrosis Factor Inhibitors
* Approaches Used in Development of Anti-TNF
* TNF Inhibitors Market Overview
* Tumor Necrosis Factor as an Anti-Cancer Agent
* Global Tumor Necrosis Factor Inhibitors Pipeline by Company, Indication and Phase
* Global Tumor Necrosis Factor Inhibitors Pipeline: 151
* Marketed Tumor Necrosis Factor Inhibitors: 25

Download Report Sample Weblink:

https://www.kuickresearch.com/report-tumor-necrosis-factor-inhibitors-market-and-clinical-pipeline-outlook-2022.php

For Report Sample Contact: neeraj@kuickresearch.com

Table of Contents

Introduction to Tumor Necrosis Factor (TNF)
1.1 Basic Structure of the Tumor Necrosis Factor (TNF) Molecule
1.2 Significance of Tumor Necrosis Factor for the Biosynthesis Regulation
1.2.1 Regulation of TNF Biosynthesis at the Transcriptional Level
1.2.2 Regulation the TNF at the Receptor Level
1.3 Tumor Necrosis Factor Receptors

Tumor Necrosis Factor Receptor Signaling Pathway
2.1 Tumor Necrosis Factor Receptor1 (TNFR1) Signaling
2.2 Tumor Necrosis Factor Receptor 2 (TNFR 2) Signaling

Overview of Tumor Necrosis Factor Inhibitors
3.1 Mechanism of Action of Tumor Necrosis Factor Inhibitors
3.2 Mechanism of Action of Remicade in the Inflammatory Diseases
3.3 Mechanism of Action of the Etanercept
3.4 Mechanism of Action of Humira

Approaches Used in Development of Anti-TNF
4.1 Monoclonal Antibody Approach
4.2 Recombinant DNA Technology Approach

Function of TNF in Immune Mediated Inflammatory Diseases
5.1 Rheumatoid Arthritis
5.2 Crohn's Disease
5.3 Psoriasis and Psoriatic Arthritis

Involvement of TNF and its Receptor in Neurodegenerative Disorders
6.1 Alzheimer’s Diseases
6.2 Parkinson’s Diseases
6.3 Ischemic Stroke
6.4 Multiple Sclerosis

Role of the Tumor Necrosis Factor in the Development of the Cancer
7.1 Introduction
7.2 Tumor Necrosis Factor as Carcinogen
7.3 Tumor Necrosis Factor as an Anti-Cancer Agent

TNF Inhibitors Market Overview
8.1 Market of Anti-TNF Blockbuster Drugs
8.1.1 Market of Humira
8.1.2 Market of Enbrel
8.1.3 Market of Remicade
8.2 Global Tumor Necrosis Factor Inhibitors Pipeline Overview

Global TNF Inhibitors Market Dynamics
9.1 Accelerative Parameters to the TNF Inhibitor Market
9.2 Challenges to the TNF Inhibitor Market

Future Implications of TNF Inhibitor Market

Global Tumor Necrosis Factor Inhibitors Pipeline by Company, Indication and Phase
11.1 Unknown
11.2 Research
11.3 Preclinical
11.4 Clinical
11.5 Phase-I
11.6 Phase-I/II
11.7 Phase-II
11.8 Phase-II/III
11.9 Phase-III
11.10 Preregistration
11.11 Registered

Marketed Tumor Necrosis Factor Inhibitors Clinical Insight
12.1 Lumbricus Rubellus Extract (Disolf)
12.2 Certolizumab Pegol (Cimzia, Simziya)
12.3 Apremilast (Otezla)
12.4 Lenalidomide (Ladevina, Revlimid)
12.5 Adalimumab (Humira, Raheara)
12.6 Etanercept (Enbrel)
12.7 Infliximab Biosimilar (Inflectra, Remsima)
12.8 Adalimumab Biosimilar
12.9 Pomalidomide (Imnovid, Pomalyst)
12.10 Belimumab (Benlysta)
12.11 Etanercept Biosimilar (Infinitam)
12.12 Golimumab (Simponi)
12.13 Infliximab Biosimilar (Infimab)
12.14 Infliximab (Remicade)
12.15 Etanercept Biosimilar (Intacept)
12.16 Iguratimod (Careram, Kolbet)
12.17 Thalidomide (Thaled, Thalidomide Celgene, Thalomid)
12.18 Infliximab Biosimilar
12.19 Adalimumab Biosimilar (Exemptia)
12.20 Etanercept Biosimilar (Iran)
12.21 Etanercept Biosimilar (Etacept, Etanar, Yisaipu)
12.22 Iguratimod
12.23 Anti-Tumour Necrosis Factor-Alpha Antibody Oral
12.24 Pentoxifylline (Claudicat, Dospan Pento, Elorgan, Pentoxifilina, Trental)
12.25 Sho-seiryu-to

TNF Inhibitors Suspended in Clinical Pipeline
13.1 No Development Reported
13.2 Discontinued
13.3 Suspended

Competitive Landscape
14.1 AbbVie
14.2 Ablynx
14.3 Apogenix
14.4 AryoGen Biopharma
14.5 Bionovis
14.6 CASI Pharmaceuticals
14.7 Celltrion
14.8 Celgene Corporation
14.9 Delenex Therapeutics
14.10 Dexa Medica
14.11 EPIRUS Biopharmaceuticals
14.12 Janssen Biotech
14.13 GlaxoSmithKline
14.14 HanAll Biopharma
14.15 Intas Pharmaceuticals
14.16 LEO Pharma
14.17 LG Life Sciences
14.18 MedImmune
14.19 Momenta Pharmaceuticals
14.20 Novartis
14.21 PROBIOMED
14.22 Reliance Life Sciences
14.23 Sandoz
14.24 Samsung Bioepis
14.25 Sanofi-Aventis
14.26 Shanghai CP Guojian Pharmaceutical
14.27 Shanghai Pharmaceuticals
14.28 Simcere Pharmaceutical
14.29 Toyama Chemical
14.30 Tsumura
14.31 UCB
14.32 Zydus Cadila

Figure 1-1: Structure of the Tumor Necrosis Factor Molecule
Figure 1-2: Regulation of the Tumor Necrosis Factor Biosynthesis and Bioavailability
Figure 1-3: Structure of Tumor Necrosis Factor Receptor 1
Figure 1-4: Structure of Tumor Necrosis Factor Receptor 2
Figure 2-1: Signaling Pathway of Tumor Necrosis Factor Receptor1 (TNFR1)
Figure 2-2: Tumor Necrosis Factor Receptor 2 Signaling Pathway (TNFR 2)
Figure 3-1: Remicade Mechanism of Action
Figure 3-2: Etanercept Mode of Action
Figure 3-3: Humira Mechanism of Action
Figure 4-1: Methods for the Anti-TNF Production
Figure 5-1: Tumor Necrosis Factor in Rheumatoid Arthritis
Figure 5-2: Global - Top Anti-Rheumatic Drug Sales (US$ Million), 2015 and 2022
Figure 5-3: Anti-TNF Therapy for the Treatment of Rheumatoid Arthritis
Figure 5-4: Molecular Targets of TNF Antagonists in Crohn’s Disease
Figure 5-5: Tumor Necrosis Factor in Psoriatic Arthritis
Figure 7-1: Tumor Necrosis Factor in the Cancer Initiation
Figure 7-2: Role of Tumor Necrosis Factor as an Anti-Cancer Agent
Figure 8-1: Blockbuster Anti-TNF Drugs (US$ Billion), 2015
Figure 8-2: Blockbuster TNF Inhibitors for Rheumatic Disease (US$ Billion), 2015 and 2022
Figure 8-3: Humira - Global Sales (US$ Billion), 2011-2015 and 2022
Figure 8-4: Enbrel - Global Sales (US$ Billion), 2011-2015 and 2022
Figure 8-5: Market Price of Enbrel and Etacept (USD)
Figure 8-6: Remicade - Global Sales (US$ Billion), 2011-2015 and 2022
Figure 8-7: Market Price of Remicade and Infimab (USD)
Figure 8-8: Global - Tumor Necrosis Factor Inhibitors Pipeline by Phase (%), 2016 till 2022
Figure 8-9: Global - Tumor Necrosis Factor Inhibitors Pipeline by Phase (Numbers), 2016 till 2022
Figure 8-10: Global - Tumor Necrosis Factor Inhibitors Suspended and Discontinued in Pipeline by Phase (%), 2016
Figure 8-11: Global - Tumor Necrosis Factor Inhibitors Suspended and Discontinued in Pipeline by Phase (Number), 2016
Figure 9-1: Favorable Parameters of Anti-TNF Drugs
Figure 9-2: Limitation Factors for the Anti-TNF Drug Market
Figure 14-1: Ablynx - Clinical Pipeline
Figure 14-2: Apogenix - Clinical Pipeline
Figure 14-3: Casi Pharmaceutical - Clinical Pipeline
Figure 14-4: Celgene - Clinical Pipeline
Figure 14-5: EPIRUS Biopharmaceuticals - Clinical Pipeline
Figure 14-6: HanAll Biopharma - Clinical Pipeline
Figure 14-7: Novartis - Clinical Pipeline
Figure 14-8: Sandoz - Clinical Pipeline
Figure 14-9: Toyama Chemical - Clinical Pipeline
Figure 14-10: Zydus Cadila - Clinical Pipeline

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Tumor Necrosis Factor Inhibitors Market and Clinical Pipeline Outlook 2022 Report here

News-ID: 1040699 • Views: 261

More Releases from Kuick Resarch

Global Cell Therapy Market To Surpass US$ 35 Billion By 2026
Global cell therapy market is expected to surpass US$ 35 Billion by 2026 as per recent report “Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026” published by Kuick Research. Increasing investment, gaining research and development activities along with new technological advancement will drive the global cell therapy market. Download Report: https://www.kuickresearch.com/report-global-cell-therapy-market,-clinical-trials,-therapy-price-and-opportunity-insight-2026.php “Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026” Report Highlights: • Global Cell Therapy
Cell Therapy Market Size Growth Cell Therapy Clinical Trials Market Forecast 202 …
Cell therapies are still in the infancy stages of the clinical development and are expected to evolve in the market with a vast number of opportunities in the healthcare industry. In order to form a stable base for process evaluation and development it will be essential to understand the quality of cell based products. With an increasing number of cell therapies and clinical indications being assessed, it is clear that
Global Cell Therapy Market Size Analysis Clinical Trials Growth Forecast 2026
"Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026" Report Highlights: • Global Cell Therapy Market Opportunity: More Than US$ 35 Billion by 2026 • Cell Therapy Clinical Trial Insight by Indication, Company & Country • Global Cell Therapy Clinical Pipeline: 767 Cell Therapies • Globally Marketed Cell Therapies: 25 Cell Therapies • Maximum Number of Marketed Cell Therapies In USA: 15 Therapies • Price & Product Insight By Region/Country • Regional Analysis of the Cell Therapy Market Download
CAR T Cell Therapy Changing The Cancer Oncology Drug Market Landscape
" Global CAR T Cell Therapy Market & Clinical Trials Insight 2024" Report Highlights: • CAR T-Cell Therapies Delivery Pipeline & Mechanism of Action • Sales Analysis of CAR - T Cell Therapy • CAR - T Cell Therapy Market Opportunity: US$ 700 Million • CAR-T Cell Therapies Clinical Pipeline by Company, Indication & Phase: 236 Therapies • CAR-T Cell Therapies in Highest Phase: Preclinical • Marketed CAR-T Cell Therapies: 2 ( Yescarta & Kymriah) • Global Market Scenario of

All 5 Releases


More Releases for Factor

Authentication Software Market Trends, Business Growth, Key Players, Application …
Global Authentication Software Market report provides a detailed market overview of the industry including definitions, classifications, applications, challenges, competitive scenario and industry chain structure. The report also analysis the Authentication Software Market verticals and horizontals, Market Size and CAGR comparison by region. The study objectives are to provide the Authentication Software market trends, future opportunities, SWOT analysis, development, key drivers, top players and their analysis etc. Major regions covered in this
Tumor Necrosis Factor Receptor
WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Tumor Necrosis Factor - Pipeline Review, H2 2017” Tumor Necrosis Factor Overview Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) pipeline Target constitutes close to 14 molecules. Out of which approximately 14 molecules are developed
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Gr …
ReportsWorldwide has announced the addition of a new report title Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary According to the recently published report 'Fibroblast Growth Factor 2 - Pipeline Review, H2 2017'; Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2)
Factor VIII Industry: Market Research to 2020
“Global Factor VIII Sales Market Report 2016” Order This Report by calling BigMarketResearch.com at +1-971-202-1575. This report studies sales (consumption) of Factor VIII in Global market, especially in USA, China, Europe, Japan, India and Southeast Asia, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering CSL Ltd. (Australia) Grifols S.A (Spain) Baxalta Incorporated (U.S.) Octapharma AG (Switzerland) Kedrion S.p.A (Italy) China Biologic Products, Inc. (China) Biotest
UV Protection Factor (UPF) of Textiles
Over exposure to ultraviolet radiation (UVR) from the sun has raised considerable public health concerns. Consumers have an increased awareness of skin cancer, eye damage (such as cataracts) and premature skin aging and as a result they are looking for protection beyond sunscreens such as lotions and creams. Depletion of the ozone layer, which protects the earth’s surface from harmful UVA, UVB and UVC rays, has forced the need for
The Chinese Factor in Brazilian Investments
Obelisk International News, Marbella, May 26 2011. As world economic power gradually shifts towards emerging markets, Chinese investments in Brazil are booming. In 2010, trade between the two countries reached an all-time high and encouraging Chinese direct investment in Brazil is key to government policy. The trade relationship between China and Brazil is relatively young, but the rate of Chinese and Brazilian investments has grown exceptionally fast. Exports from Brazil to